We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
Oral food desensitisation: are the patients safe after the end of protocol?
© Castro Moschione et al; licensee BioMed Central Ltd. 2015
Published: 30 March 2015
Desensitization protocols are increasing in food allergy centers and a higher number of patients submitted to these protocols have been showing a higher number of adverse events even after well succeed procedure. The aim of this study is to describe adverse reactions after cow's milk desensitization.
13 patients (3M: 10F, median age=11.8; 5.9-16.6) were submitted to a protocol that includes twice in a week increasing milk dose with initial dose calculated through an end point test. Adverse reactions were described according "Severity of Clinical Symptoms" by Sampson.
Before desensitization protocol all patients had presented anaphylaxis, being 9 in the last year, regarding accidental ingestion. Mean serum level of specific IgE to milk and casein were 55.24 and 47.3, respectively. From all well succeeded patients (200ml of milk at the end of protocol,) 9 patients still presented isolated reactions, being 3 Grade 1, 1 Grade 2, 0 grade 3, 5 Grade 4, 0 Grade 5. Only in 2 patients it was possible to detect a risk factor associated, that was infection, NSAIs, fasting and exercise, alcohol. In 2 patients the symptoms decreased after fractioning milk ingestion.
Although desensitization procedures are a hope for a new quality of life in these patients, more studies must be developed to guarantee a really safe future for these people.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.